KEY POINTS 

1. Product Portfolio
   Balaxi Pharmaceuticals Limited has a rich portfolio of 610 pharmaceutical product registrations. The pharma product portfolio of the company includes Tablets (46%), Injectables(17%), Liquids (12%), Capsules (13%), and Others (12%). The pharma products are sourced from WHO-GMP certified contract manufacturers based in India, China, and Portugal. [1] [2] [3]
2. Geographical Presence
   The co’s 100% of its revenues come from export sales to countries like Angola (59%), Dominican Republic (28%) & Guatemala(13%). It is in the process of expanding its operations in Honduras, El Salvador, Nicaragua, Central African Republic, and Mozambique and it is consistently expanding within its existing markets organically. [1] [4]
3. Distribution Networks
   The company has a strong distribution network of 37 warehouses and a fleet of owned vehicles across these 4 countries. It has stocked 476 new SKUs in FY22. 
4. Setting Up Manufacturing Facility
   The Co has decided to invest in establishing in-house capabilities for researching, developing, and manufacturing differentiated formulations for Latin markets. It is seeking approval to acquire 3-5 acres of land to establish its first manufacturing location in the Pharma SEZ, Telangana. It intends to establish a greenfield WHO-GMP/PICS certified manufacturing facility. This facility will be specifically focused on expanding the portfolio of differentiated branded formulations.
5. Subsidiary
   The Co’s wholly-owned subsidiary, Balaxi Global DMCC (BGD) in Dubai has acquired 2 distribution companies in Central America viz. Balaxi Healthcare Guatemala and Balaxi Healthcare Dominican Republic as its subsidiaries and incorporated a new subsidiary in Central Africa as Balaxi Healthcare Centrafrique during FY21. 
6. Acquisition
   Balaxi Global DMCC, Dubai, a wholly-owned subsidiary of the Company has completed the acquisition of 99% shares of Balaxi Healthcare El Salvador, S.A DE C.V, El Salvador, Central America (BHES), which has consequently become the Step-down subsidiary of Co. and the Shares of the acquired Company were sold by Ashish Maheshwari who is the Managing Director of co
7. Changes in KMP
   Mr. Ashish Maheshwari resigned as the interim CFO of the Co. w.e.f 20th May 2021 and Mr. Amol Mantri was appointed in his place as the permanent CFO. 
8. Change of Name
   The company has changed its name from Balaxi Ventures Limited to Balaxi Pharmaceuticals Limited in AGM held on 11th September 2020 
9. Focus
   The Company plans to set up a manufacturing facility in Hyderabad. It aims to gradually enter advanced markets like Europe.